Literature DB >> 8883124

Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report.

T Diamond1, A T Ng, S Levy, C Magarey, R Smart.   

Abstract

Parathyroid surgery is indicated in patients presenting with primary hyperparathyroidism (PHPT) and osteoporosis (defined as bone mineral density more than 2 standard deviations below normal). Many are elderly women with complex medical problems, either unwilling or considered unfit for surgery. Estrogen replacement therapy (ERT) may potentially be an alternative form of therapy in this group. We studied 15 consecutive postmenopausal women presenting with PHPT and osteoporosis. Group 1 comprised 5 women who elected to be treated with ERT (conjugated equine estrogen, 0.3-0.625 mg/day). The other 10 women underwent successful parathyroidectomy. These 10 patients were randomly subdivided into group 2 (5 patients who received calcitriol 0.25 micrograms b.i.d. for 12 months following surgery) and group 3 (5 patients who received elemental calcium 1 g/day for 12 months following surgery). Lumbar spine and femoral neck bone mineral density (BMD) were measured prior to and after 12 months of therapy, using a dual-energy X-ray absorptiometer (Lunar DPX-L). The three groups did not differ with respect to their ages (group mean 71.8 years), or baseline serum calcium (group mean 2.77 mmol/l), serum parathyroid hormone (group mean 11.0 pmol/l), lumbar spine BMD (group mean 0.93 g/cm2) and femoral neck BMD (group mean 0.73 g/cm2). Serum calcium normalized in all patients who underwent surgery and none developed hypoparathyroidism. A non-significant decrease in serum calcium was seen in patients treated with ERT only. Lumbar spine (+5.3% per year; 95% CI, 1.1% to 9.6%) and femoral neck BMD (+5.5% per year; 95% CI, -2.1% to 13.2%) increased significantly after 12 months of ERT (p < 0.001 compared with pre-therapy values). These increases in BMD did not differ significantly from those in patients who underwent successful parathyroidectomy followed by either calcitriol therapy or calcium replacement (lumbar spine BMD increase of +6.2% per year, 95% CI 3.1% to 9.4%; and femoral neck BMD increase of +3% per year, 95% CI 0 to 6%). In summary, increases in lumbar spine and femoral neck BMD occur following treatment of PHPT. ERT appeared as effective as parathyroidectomy (combined with either calcitriol or calcium supplements) for the treatment of osteoporosis in elderly postmenopausal women presenting with PHPT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883124     DOI: 10.1007/bf01623394

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  24 in total

Review 1.  Interpretation of bone mass determinations as they relate to fracture: implications for asymptomatic primary hyperparathyroidism.

Authors:  M Peacock
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

2.  Trabecular bone remodeling and balance in primary hyperparathyroidism.

Authors:  E F Eriksen; L Mosekilde; F Melsen
Journal:  Bone       Date:  1986       Impact factor: 4.398

3.  Partially reversible osteopenia after surgery for primary hyperparathyroidism.

Authors:  P Martin; P Bergmann; C Gillet; M Fuss; P Kinnaert; J Corvilain; J van Geertruyden
Journal:  Arch Intern Med       Date:  1986-04

Review 4.  Calcium-ion-sensing cell-surface receptors.

Authors:  E M Brown; M Pollak; C E Seidman; J G Seidman; Y H Chou; D Riccardi; S C Hebert
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

Review 5.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

6.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism.

Authors:  S J Silverberg; F Gartenberg; T P Jacobs; E Shane; E Siris; R B Staron; D J McMahon; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

7.  Sequential changes in bone density before and after parathyroidectomy in primary hyperparathyroidism.

Authors:  D C Leppla; W Snyder; C Y Pak
Journal:  Invest Radiol       Date:  1982 Nov-Dec       Impact factor: 6.016

8.  Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism.

Authors:  R Marcus; P Madvig; M Crim; A Pont; J Kosek
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

Review 9.  Estrogens and progestins in the management of primary hyperparathyroidism.

Authors:  R Marcus
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

10.  Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers.

Authors:  F Cosman; V Shen; F Xie; M Seibel; A Ratcliffe; R Lindsay
Journal:  Ann Intern Med       Date:  1993-03-01       Impact factor: 25.391

View more
  5 in total

1.  New perspectives in the management of primary hyperparathyroidism.

Authors:  John Ayuk; Mark S Cooper; Neil J L Gittoes
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

Review 2.  Hyperparathyroidism in the elderly patient.

Authors:  Rebecca Sims; Charanjeit Ubhi; David Hosking
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 3.  Current pharmacological options for the management of primary hyperparathyroidism.

Authors:  Peter Vestergaard
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Authors:  Munro Peacock; J P Bilezikian; M A Bolognese; Michael Borofsky; Simona Scumpia; L R Sterling; Sunfa Cheng; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

Review 5.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.